Study

Breast Cancer - Subtype defined by an amplification of the HER2 gene

Study ID Alternative Stable ID Type
EGAS00001001431 Other

Study Description

Clinically positive HER2 (cHER2+) breast cancers (BC) are defined by the amplification and overexpression of the human epidermal growth factor receptor (HER2/ERBB2) gene on chromosome region 17q12 and represent 15% of all BCs. Although anti-HER2 targeted therapies have improved BC’s natural history, the magnitude of their benefit varies widely between patients and deciphering the genomic heterogeneity of cHER2+ BC may provide a basis to better understand patients’ outcome. As part of the ICGC Breast Cancer Working Group effort, we combined whole genome sequencing and transcriptomic analyses of 64 cHER2+ primary invasive carcinomas.

Study Datasets 6 datasets.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001001844
Whole genome sequencing of 64 HER2-Positive Breast Cancer
Illumina HiSeq 2000 128
EGAD00001003189
Whole genome sequencing of 8 HER2-Positive Breast Cancer (in complement to EGAD00001001844)
Illumina HiSeq 2000 16
EGAD00010000886
samples using Affymetrix HG_U133_+2
Affymetrix HG_U133_+2 99
EGAD00010000919
samples using Illumina HUMANOMNI1QUAD
HUMANOMNI1QUAD 2
EGAD00010000920
samples using Illumina HUMANOMNIEXPRESS
HUMANOMNIEXPRESS 50
EGAD00010000921
samples using Affymetrix CYTOSCANHD
CYTOSCANHD 12

Who archives the data?

Publications

Citations

Retrieving...
Retrieving...